Therapeutic application of plasmid DNA coding for human Fas ligand in animal model of Graves disease

SUI Hua; et al

您当前的位置：

首页 >

文章列表页 >

Therapeutic application of plasmid DNA coding for human Fas ligand in animal model of Graves disease

更新时间：2024-01-17

- Therapeutic application of plasmid DNA coding for human Fas ligand in animal model of Graves disease
- Journal of Chongqing Medical University Vol. 34, Issue 12, Pages: 1640-1642(2009)
- 作者机构：
  
  1. 重庆医科大学附属第一医院内分泌科
  2. 重庆医科大学基础医学院病理学教研室
- 作者简介：
- 基金信息：
- DOI：
  CLC： R581.11
- Published：2009，
扫描看全文
[1]随华,刘纯,张徽,李秀娟,何云,张琳,詹升华.表达人Fas配体的质粒治疗Graves病模型小鼠[J].重庆医科大学学报,2009,34(12):1640-1642.

SUI Hua, et al. Therapeutic application of plasmid DNA coding for human Fas ligand in animal model of Graves disease. [J]. Journal of Chongqing Medical University 34(12):1640-1642(2009)
[1]随华,刘纯,张徽,李秀娟,何云,张琳,詹升华.表达人Fas配体的质粒治疗Graves病模型小鼠[J].重庆医科大学学报,2009,34(12):1640-1642. DOI：

SUI Hua, et al. Therapeutic application of plasmid DNA coding for human Fas ligand in animal model of Graves disease. [J]. Journal of Chongqing Medical University 34(12):1640-1642(2009) DOI：

摘要

目的:观察表达人Fas配体的质粒治疗Graves病模型小鼠的效果。方法:小鼠分为3组。对照组（10只）用空质粒pcDNA3.1（+）活化的脾细胞免疫后

以空质粒治疗;模型组和治疗组（各19只）均以人TSH受体（Human thyrotropin receptor

hTSHR）活化的脾细胞进行免疫

前者不予治疗

后者甲状腺注射表达hFasL的质粒pcDNA3.1（+）/hFasL。结果:模型组47.4%的甲状腺细胞出现增生、肥大

以及甲状腺滤泡腔胶质减少

与对照组相比

TT4、TRAb升高、TSH降低（P<0.05）。治疗组仅15.8%有类似甲状腺功能亢进改变

电镜下见细胞核异染色质边集

TT4、TSH、TRAb回复至对照组水平。结论:表达人Fas配体的质粒治疗Graves病模型小鼠取得一定效果。

Abstract

Objective:To observe therapeutic effects of plasmid pcDNA3.1/hFasL on mice with Graves’ disease.Methods:Three groups were set in this study.Animals in the control group(10 mice) were immunized with splenocytes sensitized by blank plasmid pcDNA3.1(+)

and then treated with pcDNA3.1(+).Animals in the model group(19 mice) and treated group(19 mice) were all immunized with splenocytes sensitized by hTSHR

then the latter were injected with pcDNA3.1(+)/hFasL.Results:47.4%of thyroid follicular epithelia in the model group displayed hypertrophy and hyperplasia

and the follicles cavity contained little colloid.Compared with the control group

elevated TT4 and TRAb and reduced TSH levels(P<0.05) were also observed in the model group.In the treated group

only 15.8% of thyroid follicular epithelia showed pathologic changes of GD with heterochromatin margination.There was no statistical significance in the levels of TT4

TRAb

and TSH between the treated group and the control group.Conclusion:Gene therapy by administration of plasmid pcDNA3.1/hFasL has made a curative therapeutic effects on Graves’ disease in animal model.

关键词

Graves病基因治疗Fas配体

Keywords

Graves diseasegene therapyFas ligand

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of TIMP-1 siRNA on the expression of TIMP-1 and collagen in rats with liver fibrosis

Effect of autocrine IL-4 on killing activity of CTL induced by K₅₆₂

The influence of MDR1 gene therapy on the survival rate of few late hepatocarcinoma balb/c mouse

The expression of P-gp during the MDR1 gene transferring into the hematopoietic cells of the Balb/c mouse bone marrow

Effect of retroviral HSVtk gene transfer on mice bladder tumor growth in vivo

Related Author

Zhang Yan

Lang Qing

Shi Xiaofeng

Liu Qi

Sun Hang

ZHAO Xiao-dong

et al

杨锡强

Related Institution

Department of Infectious Diseases,the Second Affiliated Hospital,Chongqing Medical University

Department of Immunology, College of Pediatrics

重庆医科大学儿科学院外科

Department of Surgery,College of Pediatrics,Chongqing Medical University

重庆医科大学儿科学院普外科

⁰